The historical rank and industry rank for Brooks Laboratories's Net Margin % or its related term are showing as below:
BOM:533543'
s Net Margin % Range Over the Past 10 Years
Min: -35.26 Med: -24.8 Max: 28.67
Current: 28.67
BOM:533543's Net Margin % is ranked better than 93.92% of 954
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs BOM:533543: 28.67
Brooks Laboratories (BOM:533543) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Brooks Laboratories Net Margin % Related Terms
Brooks Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brooks Laboratories (BOM:533543) has a Net Margin % of 7.54% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Brooks Laboratories and its competitors. According to the industry distribution chart, Brooks Laboratories ranks #58 out of 954 companies in the Drug Manufacturers industry, placing it in the top 6.1%.
Is Brooks Laboratories' Net Margin % too high?
Brooks Laboratories' current Net Margin % is 7.54%. The Drug Manufacturers industry median Net Margin % is 5.64. Brooks Laboratories' value of 7.54% is 33.8% above this industry median. Based on the distribution chart, Brooks Laboratories ranks #58 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Brooks Laboratories has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #58 out of 954 companies for Net Margin %. This places Brooks Laboratories in the top 6% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.64. Brooks Laboratories' value of 7.54% is 33.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brooks Laboratories's current Net Margin % of 7.54% is 33.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current Net Margin % is 7.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹117.81, compared to a current price of ₹77.71 — trading 34% below its estimated fair value. The current Net Margin % is 7.54% and 33.8% above the Drug Manufacturers industry median of 5.64. Brooks Laboratories' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Net Margin % is 7.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹77.71 is trading 34% below its estimated GF Value™ of ₹117.81.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
Net Margin %: 7.54%
GF Value™: ₹117.81 vs. price of ₹77.71 (34% below fair value)
Industry Position: 33.8% above the Drug Manufacturers median (#58 of 954)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
67GF Score
Get the complete analysis for BOM:533543
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 
